



HAL
open science

The Phase Diagram of the API Benzocaine and Its Highly Persistent, Metastable Crystalline Polymorphs

Ivo B. Rietveld, Hiroshi Akiba, Osamu Yamamuro, Maria Barrio, René Céolin, Josep-Lluís Tamarit

► **To cite this version:**

Ivo B. Rietveld, Hiroshi Akiba, Osamu Yamamuro, Maria Barrio, René Céolin, et al.. The Phase Diagram of the API Benzocaine and Its Highly Persistent, Metastable Crystalline Polymorphs. *Pharmaceutics*, 2023, 15 (5), pp.1549. 10.3390/pharmaceutics15051549 . hal-04102022

HAL Id: hal-04102022

<https://normandie-univ.hal.science/hal-04102022>

Submitted on 22 May 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Article

The Phase Diagram of the API Benzocaine and Its Highly Persistent, Metastable Crystalline Polymorphs

Ivo B. Rietveld^{1,2,3,*}, Hiroshi Akiba¹, Osamu Yamamuro¹, Maria Barrio^{4,5}, René Céolin⁴
and Josep-Lluís Tamarit^{4,5} 

¹ Institute for Solid State Physics, University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa 217-8581, Chiba, Japan

² Université Rouen Normandie, SMS, UR 3233, F-76000 Rouen, France

³ Faculté de Pharmacie, Université Paris Cité, F-75006 Paris, France

⁴ Grup de Caracterització de Materials, Departament de Física, EEBE, Universitat Politècnica de Catalunya, Eduard Maristany, 10-14, 08019 Barcelona, Catalonia, Spain; josep.lluis.tamarit@upc.edu (J.-L.T.)

⁵ Barcelona Research Center in Multiscale Science and Engineering, Universitat Politècnica de Catalunya, Eduard Maristany, 10-14, 08019 Barcelona, Catalonia, Spain

* Correspondence: ivo.rietveld@univ-rouen.fr

Abstract: The availability of sufficient amounts of form I of benzocaine has led to the investigation of its phase relationships with the other two existing forms, II and III, using adiabatic calorimetry, powder X-ray diffraction, and high-pressure differential thermal analysis. The latter two forms were known to have an enantiotropic phase relationship in which form III is stable at low-temperatures and high-pressures, while form II is stable at room temperature with respect to form III. Using adiabatic calorimetry data, it can be concluded, that form I is the stable low-temperature, high-pressure form, which also happens to be the most stable form at room temperature; however, due to its persistence at room temperature, form II is still the most convenient polymorph to use in formulations. Form III presents a case of overall monotropy and does not possess any stability domain in the pressure–temperature phase diagram. Heat capacity data for benzocaine have been obtained by adiabatic calorimetry from 11 K to 369 K above its melting point, which can be used to compare to results from in silico crystal structure prediction.

Keywords: active pharmaceutical ingredient; phase behaviour; pressure–temperature phase diagram; thermodynamics; crystal structure; thermal expansion; adiabatic calorimetry



Citation: Rietveld, I.B.; Akiba, H.; Yamamuro, O.; Barrio, M.; Céolin, R.; Tamarit, J.-L. The Phase Diagram of the API Benzocaine and Its Highly Persistent, Metastable Crystalline Polymorphs. *Pharmaceutics* **2023**, *15*, 1549. <https://doi.org/10.3390/pharmaceutics15051549>

Academic Editor: Andrea Erxleben

Received: 6 April 2023

Revised: 5 May 2023

Accepted: 14 May 2023

Published: 20 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

A pressure–temperature phase diagram involving the solid phases II and III of benzocaine has been reported previously [1]. The existence of a third polymorph, form I, was known at the time, but it had not been obtained during the recrystallisation experiments, and thus, the phase diagram containing exclusively the forms II and III had been constructed [1]. The II–III dimorphism represents a case of enantiotropy turning into monotropy at higher pressures, where form III is the more stable form. Enantiotropy implies that a stable equilibrium exists between two crystalline polymorphs and that by passing the equilibrium temperature at a given pressure, one polymorph will reversibly convert into the other. Monotropy indicates that one of the polymorphs is fully metastable, and thus only the transition from the metastable into the stable polymorph can be observed, whereas the reverse will not occur by a simple change in temperature. The terminology has been introduced by Lehmann based on microscopy studies with a heating stage [2]. Subsequently, Nagasako extended these notions by taking pressure into account, allowing for polymorphic systems to change their enantiotropic/monotropic behaviour as a function of pressure [3]. One of the earliest-established and better-known systems studied under pressure and temperature is that of sulphur, mentioned by Bakhuis Roozeboom [4]. It represents enantiotropy turning into monotropy with increasing pressure, which is therefore

called sulphur-type phase behaviour (Figure 1). The three other possible configurations for the phase behaviour of two polymorphs are monotropy turning enantiotropic upon increasing the pressure (the inverse of the sulphur case), overall enantiotropy (both forms maintain a domain irrespective of the pressure) and overall monotropy (one form does not possess a stable domain as a function of pressure and temperature) [4,5].




Figure 1. The pressure–temperature phase diagram of sulphur. Rhombic and monoclinic are the two polymorphs: L is the liquid and V is the vapour phase. Solid lines are stable, dashed lines are metastable, and dotted lines are supermetastable. At low pressures, both the rhombic and monoclinic forms of sulphur possess a stable domain. At a high pressure, only the rhombic form remains. This is an example of an enantiotropic system turning monotropic upon increasing pressure, as the stable domain of the monoclinic form ends at a given pressure. In the case of the previously published II–III phase diagram of benzocaine [1], the rhombic is replaced by polymorph III and monoclinic by polymorph II.

As previously published [1], benzocaine forms II and III possess a similar phase relationship as sulphur, in which rhombic is replaced by form III and monoclinic by form II (Figure 1). The availability of benzocaine form I makes it possible to demonstrate how its phase relationships can be incorporated in the existing pressure–temperature phase diagram and that its incorporation does not affect the phase relationships between phases II and III.

To verify and improve the accuracy of *in silico* crystal structure prediction, heat capacities of different polymorphs from 0 K to room temperature are of interest, so that their calculated stability hierarchies and energy contents can be compared with experimental values [6–9]. Therefore, in this paper, heat capacity data are reported starting at 10 K (with extrapolation to 0 K) for forms I and III, which both convert into form II at higher temperatures.

The absence of form I in the formerly reported phase diagram [1] highlights the fact that polymorph II, once formed, does not convert back into form I and neither, it seems, does form III; however, as the previous paper on benzocaine demonstrates [1], forms II and III readily interconvert. This makes benzocaine a system of interest to study the persistence of metastable forms to help increase the solubility of a drug by using metastable forms [10–13].

Four different crystal structures of benzocaine have been solved and can be found in the Cambridge Structural Database, although the fourth polymorph, form IV, is only stable under pressure at room temperature [14]. In Table 1, the crystal structures obtained under ordinary pressure (i.e., the vapour pressure of benzocaine as a function of the temperature and no applied hydrostatic pressure) have been listed together with a single example of form IV at 0.55 GPa. Form I crystallises in the space group $P2_1/c$ with $Z = 4$, form II in $P2_12_12_1$ with $Z = 4$, and form III in space group $P2_1$ with $Z = 8$. Form IV ($P2_1/c$, $Z = 4$) appears if form I at room temperature is subjected to a pressure of about 0.50 GPa, while form I reappears at 0.41 GPa with decreasing the pressure.

Table 1. The crystal structures in the Cambridge Structural Database obtained at a normal pressure.

Code (QQQAXG)	Form	T/K	Space Group	a	b	c	β, γ^b	$V_{\text{cell}}/\text{\AA}^3$	$v_{\text{spec}}/\text{cm}^3 \text{g}^{-1}$	Ref.
02	I	150	$P2_1/c$	8.198	5.430	19.592	91.35	871.9	0.7946	[15]
04	I	300	$P2_1/c$	8.257	5.501	19.956	91.70	906.0	0.8257	[16]
06	I	300	$P2_1/c$	8.257	5.501	19.956	91.70	906.0	0.8257	[17]
09	I	296	$P2_1/c$	8.250	5.501	19.950	91.73	905.0	0.8248	[18]
00	II	293	$P2_12_12_1$	5.307	8.222	20.869		910.6	0.8299	[19]
01	II	293	$P2_12_12_1$	5.302	8.217	20.870		909.2	0.8287	[20]
05	II	300	$P2_12_12_1$	5.311	8.242	20.904		915.0	0.8339	[16]
07	II	300	$P2_12_12_1$	5.311	8.242	20.904		915.0	0.8339	[17]
10	II	293	$P2_12_12_1$	5.309	8.236	20.866		912.4	0.8315	[18]
03	III	150	$P2_1$	8.188	10.639	20.476	99.37	1759.9	0.8020	[16]
08	III	150	$P2_1$	8.188	10.639	20.476	99.37	1759.9	0.8020	[17]
13	IV ^a	298	$P2_1/c$	6.305	5.184	24.940	96.25	810.3	0.7385	[14]

^a Only observed under pressure; for the listed unit cell parameters 0.55 GPa. ^b β for forms I and IV, and γ for form III.

In a previous paper on the benzocaine phase diagram involving forms II and III [1], the following calorimetric data have been reported: the temperature of fusion (L is liquid) of form II, $T_{\text{II} \rightarrow \text{L}} = 362.4(5)$ K, and the enthalpy of fusion of form II, $\Delta_{\text{II} \rightarrow \text{L}}H = 141(3)$ J g⁻¹, the equilibrium temperature between forms III and II, $T_{\text{III} \rightarrow \text{II}} = 265.3(5)$ K, and the enthalpy difference between forms III and II, $\Delta_{\text{III} \rightarrow \text{II}}H = 3.0(1.0)$ J g⁻¹, for the transition from form III to form II upon heating, while the reverting transition on cooling from form II to form III occurs about 5 degrees lower, at 260 K [1]. Moreover, the pressure–temperature data that have been obtained by high-pressure thermal analysis are those for the III–II transition and the melting transition, which pass through the transition temperatures ($P \approx 0$ MPa) mentioned just above [1]:

$$P_{\text{III-II}}(T)/\text{MPa} = -722(18) + 2.70(6) T/\text{K} \quad (1)$$

$$P_{\text{II-L}}(T)/\text{MPa} = -2166(50) + 5.99(13) T/\text{K} \quad (2)$$

In general, commercial batches contain form II; however, form I can be obtained by recrystallisation from ethanol (Figure 2). The stability relationships between form I and the other two forms II and III have been investigated by adiabatic calorimetry, high-pressure differential thermal analysis and powder X-ray diffraction. With the help of the topological method [1,21–23], a full pressure–temperature phase diagram of the trimorphism of benzocaine is presented.




Figure 2. A photograph of a crystal of benzocaine ($\text{C}_9\text{H}_{11}\text{NO}_2$, $165.19 \text{ g mol}^{-1}$) form I obtained from an ethanol solution.

2. Experimental

2.1. Materials

A commercial batch of benzocaine (purity $\geq 99\%$, Sigma-Aldrich, Saint-Quentin Fallavier, France) was recrystallised in ethanol. The obtained crystals (Figure 2) were taken out of the solution and left to dry completely under vacuum. Verification via X-ray diffraction demonstrated that only benzocaine form I was present in the recrystallised batch. After drying under vacuum, the recrystallised sample was used without further purification.

2.2. Adiabatic Calorimetry

The sample holder of the adiabatic calorimeter was filled with a quantity of 2.8650 g of benzocaine form I crystals, weighed on a precision balance. The description of the calorimeter has been published previously [24]. Once form I was loaded, it was cooled down to 100 K to measure the heat capacity to room temperature. No phase transition was observed. Subsequently, heat capacity measurements from about 10 K with liquid helium were carried out up until the transition from form I into form II. After this transition, the sample was cooled down again to 100 K to measure the heat capacity and observe the fully reverting form III to form II transition (form III is obtained at about 260 K by cooling form II [1]). In the final stage, the sample was cooled down to about 10 K and the heat capacity of forms III and II up until their melting and into the liquid state was obtained.

2.3. Differential Scanning Calorimetry

Differential scanning calorimetry (DSC) experiments were carried out with a conventional Q100 thermal analyser from TA Instruments. It was calibrated using the melting point of indium ($T_{\text{fus}} = 429.75$ K and $\Delta_{\text{fus}}H = 3.267$ kJ mol⁻¹). The specimens with sample masses around 10 mg were weighed with a microbalance sensitive to 0.01 mg, and sealed in aluminium pans. DSC runs were carried out with a heating rate of 2 K min⁻¹.

In addition, a PYRIS Diamond DSC from Perkin Elmer, which uses the power compensation technique, was used for differential scanning calorimetry measurements. It was calibrated using the melting point of indium (details above) and the solid–solid phase transition of cyclohexane ($T_{\text{II-I}} = 186.09$ K and $\Delta_{\text{II-I}}H = 6.686$ kJ mol⁻¹). The samples were sealed in aluminium pans and runs were carried out with a heating rate of 5 K min⁻¹.

2.4. Powder X-ray Diffraction

High-resolution X-ray diffraction as a function of temperature was performed at a standard pressure using Debye-Scherrer geometry and the transmission mode. CuK α_1 ($\lambda = 1.54056$ Å) radiation was used in a horizontally mounted INEL diffractometer with a graphite monochromator and a cylindrical position-sensitive detector (CPS-120) with 4096 channels (0.029° 2 θ -angular step). Powder samples were introduced into a 0.5 mm diameter Lindemann capillary. The temperature was controlled with a 700 series Oxford Cryostream Cooler from Oxford UK Cryosystems.

Lattice parameters as a function of temperature were determined through the isothermal acquisition of X-ray patterns between 120 K and 355 K, just below the melting point of benzocaine. Acquisitions took at least 1 h after a temperature stabilization of 15 min, while the heating rate between the measurements was 1.3 K min⁻¹. External calibration by the means of cubic phase Na₂Ca₃Al₂F₄ and cubic spline fitting was used to convert the measurement channels into 2 θ . The peak positions were determined using pseudo-Voigt fitting and the unit cell parameters were obtained from these fits using Fullprof and Topas Academic v4.1 [25–27].

2.5. High-Pressure Differential Thermal Analysis

High-pressure differential thermal analysis (HP-DTA) measurements were carried out with an in-house-constructed apparatus similar to the equipment built by Würflinger [28], operating between 0 and 300 MPa. Solid–solid transition temperatures between the different polymorphs of benzocaine and the melting temperatures as a function of pressure were

determined for specimens mixed with an inert perfluorinated liquid (Galden; Bioblock Scientifics, Illkirch, France) to eliminate air while enclosed in tin capsules. The onset of the calorimetric peaks was taken as the transition temperature.

3. Results

3.1. The I → II Transformation

The recrystallisation of benzocaine from ethanol leads to form I ($P2_1/c$), as testified by the resulting diffraction pattern in Figure 3 at 295 K. On heating, form I gradually converts into form II, which is the only form present at 353 K according to the data in Figure 3.




Figure 3. Benzocaine form I at 295 K (22 °C) after recrystallisation in ethanol. At 313 K (40 °C), form I still appears to be stable; however, further heating slowly leads to the formation of form II starting at 335 K (62 °C), as demonstrated by two measurements, 1 h each, at this temperature. Form II is clearly the only polymorph present at 353 K (80 °C). The diffraction patterns of phases I and II (in black) have been provided based on single-crystal diffraction data from the CSD.

From the DSC data in Table 2 and the DSC curve in Figure S1 in the Supplementary Materials, it can be seen that the transformation of form I into form II is a slow and not very well controlled process. In many cases, two peaks are observed (Table 2 and Figure S1) and the enthalpy varies considerably. Nonetheless, the peaks can most likely be ascribed to the I → II transition based on the observations of the X-ray diffraction in Figure 3. Considering that the peaks in the DSC curve around 317 and 340 K are both related to the I → II transition, a clear temperature for the phase equilibrium cannot be given. The average combined enthalpy amounts to 1.6 J g^{-1} for the TA instruments and 2.0 J g^{-1} for the Perkin Elmer. Averaging over both machines leads to a value of 1.8 J g^{-1} , although the variability most likely indicates that the enthalpy of the transition is mostly underestimated and the real transition enthalpy may be close or even above the highest observed value of 3.0 J g^{-1} (the combined transition of sample 8 in Table 2). The melting enthalpy difference and temperature averaged over all measurements are $132(3) \text{ J g}^{-1}$ and $362.1(1.0) \text{ K}$ (88.9 °C), respectively.

Table 2. The transformation of form I into form II and fusion of benzocaine form II, as obtained by two differential scanning calorimeters (see also Figure S1 in the Supplementary Materials).

Sample	Mass/mg	T/K	Peaks I → II		Fusion		
			$\Delta H/J\ g^{-1}$	T/K	$\Delta H/J\ g^{-1}$	T/K	$\Delta H/J\ g^{-1}$
TA instruments							
1	3.84	316.8	0.67	340.2	1.09	362.6	132.9
2	3.11			341.6	0.89	362.6	137.5
3	7.89	317.0	1.70			362.8	127.4
4	1.66			340.0	1.86	362.6	129.9
5	2.42			342.4	2.63	362.6	134.4
6	3.70	318.0	0.03	344.2	1.54	362.6	133.5
7	4.44	317.6	0.50	339.2	0.61	362.6	131.0
Perkin Elmer							
8	2.46	321.0	0.76	339.6	2.24	359.8	129.9
9	2.08	316.2	0.62	332.6	1.97	361.4	127.5
10	2.15			336.2	0.90	361.8	131.5
11	2.42			343.8	1.67	361.4	133.1

3.2. The Thermal Expansion of Benzocaine

The unit cell parameters of form I as a function of temperature have been compiled in Table S1 in the Supplementary Materials (see Section 2.4 for the measurement procedure). It leads to the following expression for the specific volume of form I as a function of temperature obtained between 120 K and 320 K:

$$v_I(T)/\text{cm}^3\ \text{g}^{-1} = 0.788(3) + 3.8(2.2) \times 10^{-5} T/\text{K} + 3.0(5) \times 10^{-7} T^2/\text{K} \quad (3)$$

Within the fitting range, the average deviation of this expression in relation to the measured data is less than 0.1%.

To ensure that the volume differences between the polymorphs are consistent, the diffraction of the other two polymorphs has been measured with the same experimental settings and with the same sample as form I. These specific volumes match with the error of the previously obtained data [1]. The unit cell parameters of forms II and III as a function of temperature can be found in Tables S2 and S3, respectively, in the Supplementary Materials. These data lead to the following expressions for the specific volume of forms II and III of benzocaine:

$$v_{II}(T)/\text{cm}^3\ \text{g}^{-1} = 0.835(30) - 2.19(1.99) \times 10^{-4} T/\text{K} + 7.15(3.27) \times 10^{-7} T/\text{K} \quad (4)$$

$$v_{III}(T)/\text{cm}^3\ \text{g}^{-1} = 0.798(3) - 2.78(2.85) \times 10^{-5} T/\text{K} + 4.91(74) \times 10^{-7} T/\text{K} \quad (5)$$

The average error of these fits within their fitting ranges is 0.13% (form II, 250–355 K) and 0.05% (form III, 120–255 K). Moreover, it can be seen in Figure 4 that form I is the densest form (Equation (3)) as it has the lowest specific volume from the lowest measured temperature to its equilibrium with form II. Form III has a slightly lower density (Equation (5)), and the least dense form is form II (Equation (4)).




Figure 4. Specific volumes of forms I (filled circles), II (filled squares), and III (filled triangles) obtained by powder X-ray diffraction in the current study. Single-crystal literature data are indicated by open symbols.

3.3. Heat Capacity, Entropy, Enthalpy, and Gibbs Free Energy Obtained via Adiabatic Calorimetry

The heat capacity of form I has been measured by adiabatic calorimetry from 12.6 K onwards, while the heat capacity below that temperature has been obtained by extrapolation with Equation (S1) (see Figure 5 and Table S4 in the Supplementary Materials). Form I turns into form II at 319.5 K, as indicated by the relatively broad peak (red line in Figure 5), which compares with the slow conversion of form I into form II as observed by DSC. The entropy and enthalpy involved with this transformation and obtained via adiabatic calorimetry can be found in Table 3.




Figure 5. Heat capacity data of forms I (green triangles) and III (blue circles), turning into form II at the respective peaks, followed by the melting peak (in blue).


Table 3. Temperature, entropy, and enthalpy of transition obtained with adiabatic calorimetry.

Equilibrium	T /K	ΔS /J g ⁻¹ K ⁻¹	ΔH /J g ⁻¹
III-II	266.0	0.010225	2.7194
I-II	319.5	0.011938	3.8146
II-L	361.0	0.369514	133.412

Once converted into form II, the heat capacity was once again measured from 11.4 K onwards, with an extrapolation to 0 K by Equation (S2) in the Supplementary Materials. The data can be found in Table S4 in the Supplementary Materials. Upon cooling, form II turns into form III at about 260 K depending on the cooling rate, which is the actual polymorph measured at a low temperature. A peak is observed (blue line in Figure 5) at 266.0 K, indicating the transition from form III to form II, which then melts at 361.0 K. The entropy and enthalpy changes of the two transitions obtained via adiabatic calorimetry have been compiled in Table 3.

3.4. Transition Temperatures Obtained under Pressure

The analysis of the pressure–temperature phase diagram, which will follow in the discussion, led to the realisation that the I–II and I–L phase equilibria were accessible for measurement in the high-pressure differential thermal analyser. Hence, the samples of form I have been loaded in tin capsules and measurements as a function of temperature for a given pressure have been carried out. Moreover, further analysis of the phase diagram demonstrated that form I could be regained through crystallising the melt at high pressure and cooling down. The peaks indicating that form I is obtained again can be observed in Figure 6.

**Figure 6.** High-pressure differential thermal analysis of the I–II transition (inset), and the melting peaks of either form II (lower pressure) or form I (higher pressure).

The transition pressures as a function of temperature of the two-phase equilibria I–II, II–L and I–L, obtained via HP-DTA in the current study have been compiled in Table S5

in the Supplementary Materials. They result in the following equations of the transition pressure (P/MPa) fitted to the data:

$$P_{\text{I-II}}/\text{MPa} = -598(22) + 1.89(7) T/\text{K} \quad R^2 = 0.992 \quad (6)$$

$$P_{\text{II-L}}/\text{MPa} = -2350(128) + 6.5(4) T/\text{K} \quad R^2 = 0.98 \quad (7)$$

$$P_{\text{I-L}}/\text{MPa} = -2131(121) + 5.9(3) T/\text{K} \quad R^2 = 0.989 \quad (8)$$

4. Discussion

4.1. Stability of Benzocaine under Ordinary Pressure: Adiabatic versus DSC

The stability of the different polymorphs can be directly obtained from the heat capacity data, which have been converted to entropy, enthalpy, and Gibbs free energy in Tables S6 and S7 in the Supplementary Materials. The Gibbs free energy of form I has been set to zero at 0 K, resulting in a positive Gibbs free energy of 197.4 J mol^{-1} for form III. The Gibbs free energies of forms III and II meet at 266 K and there should be a slight change in the slope in the blue curve in Figure 7. The Gibbs free energy of form I meets that of form II at 319.5 K, where both the green curve and the blue curve in Figure 7 become identical. A final change in the slope of the blue curve should occur at 361.0 K, where form II is replaced by the liquid as the most stable phase.




Figure 7. Gibbs free energy of form I (green triangles) and form III (blue circles), which become equal once both forms have turned into form II (bottom right-hand figure). Form III has a higher Gibbs free energy (top right-hand figure), and is therefore less stable than form I. Form I remains the most stable form to 319.5 K.

Comparison between Tables 2 and 3 demonstrates that the I–II transition possesses indeed a higher transition enthalpy than obtained with DSC, which is probably due to the fact that part of the solid–solid transition is not fully observed by DSC, because the signal may be spread over a larger temperature domain and fade into the baseline. This highlights the importance of adiabatic calorimetry, which clearly provides better equilibrium data for slow solid–solid transitions. The melting enthalpy obtained with the recent batches is slightly smaller for the values obtained with DSC. Although the scatter is relatively large and within the measurement error, the DSC and adiabatic calorimetric melting data are the same. The previously published DSC data on forms II and III appear to be a little higher than the adiabatic calorimetric data. The reason for this is not clear. The calibration of the DSC will have been different, and a different batch of benzocaine was used.

4.2. Construction of the Pressure–Temperature Phase Diagram

4.2.1. High-Pressure Data and Its Triple Points

In Figure 8, the high-pressure data (solid circles) and the fitted lines (Equations (1) and (6)–(8)) have been plotted. The previously measured II–L equilibrium (Equation (2)) has not been used, because the fit may have been based on the melting equilibria of both form I and form II. It can be seen that both II–L and I–L (Equations (7) and (8), respectively) are very close to the former equilibrium Equation (2). From this experimental phase diagram, it is immediately clear that at 0 MPa, form II melts at the highest temperature (purple line) and that a stable I–II equilibrium occurs slightly above 300 K. The blue–purple triangle that is formed with the dashed 0 MPa baseline represents the small P–T domain in which form II is stable. Form I is stable on the upper left-hand side of the blue line and the III–II equilibrium, the green line, must be metastable. Because form I is stable above the blue I–II equilibrium, the red dotted line, representing the melting of form I, becomes stable once it intersects the blue line towards higher pressures, while it is found at the right-hand side of the purple II–L equilibrium. The intersection of the blue, purple, and red lines is the stable I–II–L triple point, of which the coordinates are listed in Table 4 below. Moreover, the intersection of the green III–II and purple II–L equilibria provides the position of the III–II–L triple point. Finally, the green III–II and blue I–II equilibria intersect at a negative pressure at the I–II–III triple point. Each intersection of the four two-phase equilibria, with their respective vapour phase pressures, close to 0 MPa (and approximated by the dashed black line), represents a triple point involving the vapour phase, v , (Table 4, in order of increasing temperature): III–II– v , I–II– v , I–L– v , II–L– v . Here, the triple-point temperature of III–II– v is determined with Equation (1), which equals to 267.8 K at the MPa value of 0. For the triple point I–II– v , Equation (6) is used, leading to a temperature of 316.6 K. In the same way, the triple point of II–L– v is determined with Equation (8), leading to 359.5 K, while the triple point temperature II–L– v follows from Equation (7) and gives rise to 362.0 K. The calculations of the triple points have been carried out with the equations within which the parameters have not been rounded off, and the resulting triple-point temperatures may therefore differ slightly if the equations are used as listed in this paper.




Figure 8. The pressure–temperature phase diagram based exclusively on the obtained HP-DTA data measured in the current study (equilibrium I–II dark blue, equilibrium II–L purple, equilibrium I–L red) and previously measured data (equilibrium III–II green) [1].

The remaining question is the position of the I–III equilibrium and connected to this, the position of the III–L equilibrium. This will be solved in a topological manner, as discussed in the next section.

Table 4. Triple points involving polymorphs I, II, and III of benzocaine.

Triple Point	Temperature/K	Pressure/Pa	
I–II–III	154.0	-307×10^6	metastable
III–II– <i>v</i>	267.8	0.012	metastable
I–II– <i>v</i>	316.6	2.4	stable
I–III–L	326.1	-198×10^6	supermetastable
III–L– <i>v</i>	358.3	78	supermetastable
I–L– <i>v</i>	359.5	83	metastable
II–L– <i>v</i>	362.0	95	stable
I–II–L	380.1	120×10^6	stable
III–II–L	428.9	435×10^6	metastable
I–III– <i>v</i>	639.3	7.4×10^6	supermetastable

4.2.2. The Positions of the I–III and the III–L Equilibria

The positions of the I–III and the III–L equilibria in the phase diagram are closely linked. It is, however, easiest to locate the I–III equilibrium, because its position has more dramatic consequences for the phase behaviour of benzocaine. In Figure 8, there is one triple point, I–II–III, at a low temperature and negative pressure, which must be intersected by the I–III equilibrium. From Equations (3) and (5) and Figure 4, it can be seen that form I has a smaller specific volume, thus form I is the stable high-pressure form in relation to form III according to Le Chatelier. The differences in entropy of the polymorphs I and III in relation to form II are listed in Table 3. The entropy change going from form III to form II is smaller than the entropy change for form I to form II. This implies that form III contains more entropy and is therefore the high-temperature form in relation to form I. The same conclusion can be reached by comparing the entropies listed in Tables S6 (form I) and S7 (form III). Thus, simply considering the global inequalities in the volume and entropy, it is found that in relation to the I–III equilibrium, form I is the low-temperature, high-pressure form and form III is the high-temperature, low-pressure form; in other words, the phase equilibrium between the two polymorphs has a positive slope with form I on the upper left-hand side and form III on the lower right-hand side.

Taking the I–II–III triple point ($T = 154$ K and $P = -307$ MPa) as a pivot for the I–III equilibrium, and taking into consideration its positive slope, three topological scenarios exist: (1) I–III with a steeper slope than III–II and I–II, (2) I–III with a less steep slope than III–II, but a steeper slope than I–II, and (3) I–III with a shallower slope than both other solid–solid equilibria. It should be kept in mind that form I is stable above the equilibrium and form III below it. In the case of scenario (1), form I will be stable at high pressure and low temperature. Form III will appear on crossing this equilibrium, which will then turn into form II on crossing from the top–left III–II equilibrium; however, at that point, form II is still metastable with respect to form I, and that implies that form III is also still metastable with respect to form I, which creates an inconsistency in the phase behaviour. A similar inconsistency exists for scenario (2): form I, which is stable according to the phase diagram in Figure 8, turns into form III, which must be metastable, because form II is the more stable form. This implies that form I must be metastable towards form II, but that only occurs once the blue I–II equilibrium is crossed. Thus, the only viable scenario is number (3), for which the slope of the I–III equilibrium is the smallest of the three solid–solid equilibria and the line is therefore found below the I–II phase equilibrium. This also implies that the I–III equilibrium is completely metastable, because neither form I nor form III are stable below the I–II equilibrium, implying that Figure 8 already covers the full stable phase diagram. The remaining unknown is the slope of the I–III equilibrium and where it precisely intersects the vapour phase pressure close to 0 MPa, which would represent the I–III transition under ordinary conditions (i.e., in the calorimeter).

There are several approaches to estimate the slope of the I–III equilibrium, of which the following two are the most direct: (1) by calculating the slope using the Clapeyron equation, or (2) by calculating the I–III–*v* (*v* = vapour) triple point, the transition temperature at a standard pressure (0 MPa), using an equation proposed by Yu [29]. With option (1), the slope with the I–II–III triple point will define the position of the equilibrium expressed as a straight line, and with option (2), a straight line drawn through the two triple points I–II–III and I–III–*v* will define the position of the equilibrium. Because both are abstract extrapolations, neither will necessarily represent the realistically precise position of the equilibrium, but topologically, it will provide the correct interpretation of the phase behaviour, which should be thermodynamically consistent.

Using option (1), the calculation of the slope necessitates the Clapeyron equation:

$$\frac{dP}{dT} = \frac{\Delta S}{\Delta v} \quad (9)$$

in which dP/dT is the slope in the pressure–temperature phase diagram, ΔS is the entropy difference and Δv is the volume difference between the two phases, I and III. ΔS follows from Table 3 (or the Tables S6 and S7 in the Supplementary Materials) and is $\Delta_{I \rightarrow III} S = \Delta_{I \rightarrow II} S - \Delta_{III \rightarrow II} S = 0.011938 - 0.010225 = 0.001713 \text{ J g}^{-1} \text{ K}^{-1}$. In an ideal case for the difference in volume, the volume at the transition temperature under standard conditions should be taken, but this value is unknown and located at a higher temperature than that where forms III and I can be obtained. Therefore, it is more convenient to choose a temperature at which both volumes are accurately defined, such as 225 K, using the Equations (3) and (5). This leads to $v_I = 0.81221 \text{ cm}^3 \text{ g}^{-1}$ and $v_{III} = 0.81613 \text{ cm}^3 \text{ g}^{-1}$, and thus to a difference of $\Delta_{I \rightarrow III} v = v_{III} - v_I = 0.00392 \text{ cm}^3 \text{ g}^{-1}$. Using the Clapeyron equation Equation (9), this leads to a slope of $0.4375 \text{ MPa K}^{-1}$, and using the triple point I–II–III (Table 4), a tentative equation for the I–III equilibrium is obtained: $P_{I-III}/\text{MPa} = -374 + 0.437 T/\text{K}$. It can be seen that the slope is indeed much less than that of the III–II equilibrium (Equation (1)), with 2.70 MPa K^{-1} or the I–II equilibrium with 1.89 MPa K^{-1} (Equation (6)). Through this equation for the I–III equilibrium, the triple-point temperature of I–III–*v* is found to be 856 K.

Using option (2) requires an equation proposed by Yu to calculate the solid–solid transition temperature [29]:

$$T_{I \rightarrow III} = \frac{\Delta_{III \rightarrow L} H - \Delta_{I \rightarrow L} H}{\Delta_{III \rightarrow L} S - \Delta_{I \rightarrow L} S} = \frac{\Delta_{II \rightarrow L} H + \Delta_{III \rightarrow II} H - (\Delta_{II \rightarrow L} H + \Delta_{I \rightarrow II} H)}{\Delta_{II \rightarrow L} S + \Delta_{III \rightarrow II} S - (\Delta_{II \rightarrow L} S + \Delta_{I \rightarrow II} S)} = \frac{\Delta_{III \rightarrow II} H - \Delta_{I \rightarrow II} H}{\Delta_{III \rightarrow II} S - \Delta_{I \rightarrow II} S} \quad (10)$$

As most of the transition enthalpies and entropies are not known, because only the fusion of form II has been measured, Equation (10) has been rewritten to provide the transition temperature between forms I and III using form II instead of the liquid phase, which is thermodynamically completely equivalent to the proposed equation by Yu involving the liquid phase. This leads to a temperature for the I–III–*v* triple point of 639 K. As this is at “ordinary pressure”, the pressure value will be approximated with 0 MPa. Then, with the I–II–III triple point at 154 K and -307 MPa , the following equation for the I–III equilibrium can be obtained: $P_{I-III}/\text{MPa} = -404 + 0.633 T/\text{K}$. Again, it can be seen that the slope is rather small and much less than the slopes of the I–II and II–III equilibria, and the two scenarios can be considered to roughly represent the error margin of the I–III equilibrium, which will always be metastable and out of reach of measurement.

To draw the topological phase diagram, the latter expression will be chosen (there is no scientific ground to choose one expression over the other):

$$P_{I-III}/\text{MPa} = -404 + 0.633 T/\text{K} \quad (11)$$

Once the position of the I–III equilibrium has been defined, it also defines the position of the melting equilibrium of form III, because the I–III equilibrium will intersect the I–L equilibrium, leading to the triple point I–III–L. Thus, with Equations (8) and (11), the

following coordinates are found: 326 K and -198 MPa. Another triple point of the III–L equilibrium is III–II–L, which can be calculated with the measurement Equations (1) and (7). The triple-point coordinates are 429 K and 435 MPa. Therefore, the III–L equilibrium passing through these two points possesses the following equation:

$$P_{\text{III-L}}/\text{MPa} = -2204 + 6.15 T/\text{K} \quad (12)$$

Using this equation, the melting point of form III can be determined, as this will occur at 0 MPa (ordinary pressure), leading to 358.3 K. This value, obtained through the extrapolation of the topological phase diagram, can be compared with the melting point that would be obtained by the equation proposed by Yu, and then modified to obtain a melting transition [1]:

$$T_{\text{III} \rightarrow \text{L}} = \frac{\Delta_{\text{II} \rightarrow \text{L}}H + \Delta_{\text{III} \rightarrow \text{II}}H}{\frac{\Delta_{\text{II} \rightarrow \text{L}}H}{T_{\text{II} \rightarrow \text{L}}} + \frac{\Delta_{\text{III} \rightarrow \text{II}}H}{T_{\text{III} \rightarrow \text{II}}}} = \frac{\Delta_{\text{II} \rightarrow \text{L}}H + \Delta_{\text{III} \rightarrow \text{II}}H}{\Delta_{\text{II} \rightarrow \text{L}}S + \Delta_{\text{III} \rightarrow \text{II}}S} \quad (13)$$

Using the values from Table 3, this leads to the melting point of form III of 358.5 K, so the differences in this case are negligible. It can also be concluded that form III is the lowest-melting form, followed by form I, while form II is the highest-melting form (Table 4). Another observation that can be made is that the slope of the II–L equilibrium, 6.5 MPa K^{-1} , is the steepest slope, while III–L has a slightly shallower slope of 6.15 MPa K^{-1} and form I has the gentlest slope with 5.9 MPa K^{-1} . This sequence in the slopes leads to a stable melting equilibrium for form I at high pressure, whereas the melting equilibrium of form III is placed in such a way that it never becomes stable, reflecting the metastability of form III.

4.2.3. The Pressure–Temperature Phase Diagram

In a pressure–temperature phase diagram with three solid phases, the liquid and the vapour phase, ten triple points must be present, which represent the ten possible intersections between the six two-phase equilibria [30]. All triple points have been listed in Table 4, based on the measured phase equilibrium data with the high-pressure differential thermal analysis. Only, when necessary, as in the case of the slope of the I–III equilibrium enthalpy and entropy values obtained via adiabatic calorimetry have been used. Therefore, there are small differences between the transition temperatures obtained via HP-DTA and DSC or adiabatic calorimetry, which can be considered the uncertainty over the measurements. Moreover, it is possible to calculate the vapour pressure of the condensed phases using the Clausius–Clapeyron equation, and the boiling temperature and enthalpy of vaporization obtained through ACD-Labs [31], as it has previously been carried out for the equilibria involving the vapour phase and forms II and III [1]. This approach is explained in detail in the Supplementary Materials. The calculated vapour pressures of the respective triple points have been compiled in Table 4 (see also Tables S8 and S9 in the Supplementary Materials).

The resulting topological phase diagram is presented in Figure 9 on the left-hand side. For the sake of clarity, the melting equilibria (triple points 1, 2, and 3) have been separated in an exaggerated way. The stable vapour-phase equilibria defining the lower limit of the stable condensed phases are given by the sequence f-7-1-a. The stability domain of form II is defined by the black triangle 1-4-7, and above this triangle f-7-4-c, defines the stability domain of form I. Form III becomes more stable than form I below the equilibrium line indicated by 'j', but its position is such that the vapour phase has the lowest Gibbs free energy and is thus the more stable phase. The stable phase diagram of benzocaine with the phases I, II, liquid, and vapour, can be found in the right-hand panel of Figure 9. The temperature and pressure axes are to scale.




Figure 9. **Left-hand panel.** Topological phase diagram of the three polymorphs of benzocaine together with the liquid and vapour phases. The 10 triple points have been numbered and are listed in the graph, as are the different two-phase equilibrium lines. Black indicates stable, blue metastable, red supermetastable, and green hypermetastable. Form I is stable in the upper left-hand corner defined by the black lines, the liquid is stable in the upper right-hand corner defined by the black lines, the vapour is stable below the black lines, and form II is stable within the triangle formed by the black lines. A close-up of the triple points 1, 2, 3, 7, and 8 involving the vapour phase equilibria can be found in Figure S2 in the Supplementary Materials. **Right-hand panel.** Stable phase diagram of benzocaine with the pressure and temperature axes to scale. It should be noted that the vapour pressure equilibria (lines marked on the left with e, f, and g) are now fully superposed. Form III, which does not possess a stable domain, is absent in this diagram. Form IV stabilizes somewhere above 0.5 GPa at room temperature. The stability hierarchy is indicated similarly to Figure 1: solid lines and circles are stable two-phase equilibria and stable triple points, respectively, the dashed lines and grey circles indicate metastable, and dotted lines indicate supermetastable.

Although the phase diagram involving three phases seems rather complicated, it should be realised that it consists of a sum of three dimorphism phase diagrams, the first being the previously published III–II phase diagram, where both form III and form II have a stable temperature domain at a standard pressure (enantiotropy), whereas the system becomes monotropic at higher pressures (see blue lines and point 5 in Figure 9) with form III, i.e., the single more stable form. This phase behaviour is similar to that of sulphur (Figure 1) [4]. The second phase diagram is that of forms I and II, which presents a very similar behaviour as forms II and III, except that now, form I is the high-pressure form (see black lines in Figure 9). As both form I and form III compete for the high-pressure, low-temperature domain, the third phase diagram, that of forms I and III, demonstrates that form III is less stable than form I. In fact, when form III finally has a lower Gibbs energy than form I, it is always the vapour that possesses an even lower Gibbs energy. The I–III equilibrium is indicated by the line j–j, which is mostly green (hypermetastable). Due to the overall monotropy between forms I and III, form III does not possess any stable pressure–temperature domain.

The pressure–temperature phase diagrams related to dimorphism are relatively easy to understand, because they only contain four triple points, and therefore only four possible cases exist, which have been described by Bakhuis Roozeboom [4]. These four cases are overall monotropy (benzocaine I–III), overall enantiotropy, as in the case of gestodene [32], enantiotropy turning monotropic upon increasing pressure (benzocaine II–III and I–II) and the inverse case, monotropy turning enantiotropic upon increasing pressure, of which ritonavir is an example [22]. The four resulting pressure–temperature phase diagrams can be found in a recently published paper [5].

Trimorphism, shown in Figure 9, becomes rapidly more complicated to describe than dimorphism, and in the literature, only four other papers report on topological phase diagrams involving trimorphism [33–36] and one other concerning tetramorphism [13]. In the case of the trimorphism of ferrocene [33], one of the phases is also overall metastable. As in the case of sulphur [4], the two other phases of ferrocene are overall enantiotropic, exhibiting stable domains irrespective of the pressure. For piracetam, all three forms

have their stable domain, but only one remains stable under higher pressure, i.e., the system becomes fully monotropic [34]. In the case of 2-methyl-2-chloropropane, two solid phases are overall enantiotropic, whereas the third one becomes monotropic at a high pressure [36]. In the case of l-tyrosine ethyl ester, again, a sulphur-type phase behaviour between the two phases is encountered, whereas the third phase appears to exhibit a stable domain at an extremely low temperature, so all three phases are stable in their respective temperature domain at low pressure [35]. A similar line-up of stability domains as a function of temperature is observed for tetramorphic pyrazinamide, while under higher pressure, only two polymorphs remain [13]. Thus, even within this small collection of samples, many different combinations of phase behaviour are encountered.

5. Conclusions

Adiabatic calorimetry and high-pressure differential thermal analysis both lead to the conclusion that benzocaine form I possesses the largest stability domain, and that form II is only stable in a small pressure–temperature domain before melting. Full consistency exists between the outcomes of the two methods. A combination of the adiabatic calorimetry with powder X-ray diffraction for the specific volumes and the high-pressure measurements has led to a complete topological pressure–temperature phase diagram (Figure 9), in which it is demonstrated that form III does not possess any stable domain (Figure 9 and Figure S2 in the Supplementary Materials). This case is a prime example of how phase behaviour can be added up and that the relative hierarchy between the phases does not change, while the absolute hierarchy is adapted as a function of the stability behaviour of a new phase. Form IV [14], for example, can be added to this phase diagram, once more information about its phase relationship with form I is obtained. It should also be clear that adiabatic calorimetry is much more reliable in finding equilibrium conditions than differential scanning calorimetry (DSC).

Even though form I is not the commercially available polymorph, adiabatic calorimetry has demonstrated that it is the most stable form from 0 K to $T_{I-II} = 319.5$ K. Nonetheless, form II is the commercial form, and it does not appear to transform at all into form I under standard conditions at room temperature, despite its metastable character, with respect to form I. The only way to obtain form I appears to be through the crystallisation of ethanol. However, while constructing the topological phase diagram of benzocaine, it became clear that the I–II–L triple point (point 4 in Figure 9) was in reach of the limits of the HP-DTA equipment, and that the melting equilibrium of form I could be observed. This has also led to the assumption that by melting form II, increasing the pressure, and lowering the temperature, once above the I–II–L triple point pressure, form I may crystallise instead of form II. The appearance of the I–II transition in subsequent runs confirmed this assumption (Figure 6).

Interestingly, form III, which appeared to be a low-temperature, high-pressure polymorph, at least with respect to form II [1], is in fact a high-temperature, low-pressure form in relation to the more stable form I. The reason that form III appears at all, is that once polymorph II has formed, it has never been observed to convert back into form I; therefore, commercial batches contain form II. Due to this persistence, form III can appear at low temperatures as a means for the system to lower its energy towards form I, even if the system remains trapped, as a direct transition between form I and form III has never been observed either.

For pharmaceutical applications, these findings imply that form II can be safely used for the development of solid-state formulations. This would render the formulations safe against high temperatures. The reason why polymorphs II and III are so persistent in relation to a more stable form should be investigated more thoroughly, so that a drug molecule may be designed with highly persistent metastable polymorphs, which leads to improved solubilization and bioavailability.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmaceutics15051549/s1>, Figure S1: An example of the appearance of the I-II transition in a DSC measurement; Table S1: Unit-cell parameters of form I ($P2_1/c$, $Z = 4$) as a function of temperature; Table S2: Unit-cell parameters of form II ($P2_12_12_1$, $Z = 4$) as a function of temperature; Table S3: Unit-cell parameters of form III ($P2_1$, $Z = 8$) as a function of temperature; Table S4: Heat capacity of benzocaine forms I, II, and III as a function of temperature obtained by adiabatic calorimetry. Equation S1: Form I Cp extrapolation to 0 K; Equation S2: Form III Cp extrapolation to 0 K; Table S5: Temperature-pressure data of the I-II, I-L, and II-L equilibria; Table S6: Entropy (S), Enthalpy (H), and Gibbs free energy (G) of the stable form I and form II as obtained from the heat capacity measurements; Table S7: Entropy (S), Enthalpy (H), and Gibbs free energy (G) of the stable form I and form II as obtained from the heat capacity measurements; Text: Clausius-Clapeyron equation and the vapor pressures of the condensed phases; Table S8: Vapor pressure calculations; Table S9: Vapor pressures of individual phases at triple points; Figure S2: Schematic close-up of the melting and vapor equilibria in the pressure-temperature phase diagram of benzocaine including the vapor equilibria.

Author Contributions: Conceptualization, I.B.R. and R.C.; methodology, I.B.R., O.Y. and R.C.; formal analysis, I.B.R., H.A., O.Y., M.B. and J.-L.T.; investigation, I.B.R., H.A., M.B. and O.Y.; resources, O.Y. and J.-L.T.; writing—original draft preparation, I.B.R.; writing—review and editing, I.B.R., R.C., M.B. and J.-L.T.; funding acquisition, O.Y. and J.-L.T. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Spanish AEI/MCIN through Project PID2020-112975GB-I00, and by the Catalan Government Grant No. 2021SGR-00343.

Data Availability Statement: Most data is available in the paper or in the supplementary materials. Any additional information can be obtained upon request.

Acknowledgments: The authors thank Kangli Li for the photograph in Figure 2. I.B.R. thanks Tokyo University for financial support for his stay at the Institute for solid state physics.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Gana, I.; Barrio, M.; Do, B.; Tamarit, J.-L.; Céolin, R.; Rietveld, I.B. Benzocaine polymorphism: Pressure-temperature phase diagram involving forms II and III. *Int. J. Pharm.* **2013**, *456*, 480–488. [[CrossRef](#)] [[PubMed](#)]
2. Lehmann, O. *Molekularphysik*; Verlag von Wilhelm Engelmann: Leipzig, Germany, 1888; Volume 1.
3. Nagasako, N. On enantiotropy and monotropy. I. *Bull. Chem. Soc. Jpn.* **1928**, *3*, 90–95. [[CrossRef](#)]
4. Bakhuis Roozeboom, H.W. *Die Heterogenen Gleichgewichte vom Standpunkte der Phasenlehre. Erstes Heft: Die Phasenlehre—Systeme aus einer Komponente*; Friedrich Vieweg und Sohn: Braunschweig, Germany, 1901; Volume 1.
5. Ceolin, R.; Rietveld, I.-B. X-ray crystallography, an essential tool for the determination of thermodynamic relationships between crystalline polymorphs. *Ann. Pharm. Fr.* **2016**, *74*, 12–20. [[CrossRef](#)] [[PubMed](#)]
6. Reilly, A.M.; Cooper, R.I.; Adjiman, C.S.; Bhattacharya, S.; Boese, A.D.; Brandenburg, J.G.; Bygrave, P.J.; Bylisma, R.; Campbell, J.E.; Car, R.; et al. Report on the sixth blind test of organic crystal structure prediction methods. *Acta Crystallogr. B* **2016**, *72*, 439–459. [[CrossRef](#)] [[PubMed](#)]
7. Addicoat, M.; Adjiman, C.S.; Arhangelskis, M.; Beran, G.J.O.; Bowskill, D.; Brandenburg, J.G.; Braun, D.E.; Burger, V.; Cole, J.; Cruz-Cabeza, A.J.; et al. Crystal structure evaluation: Calculating relative stabilities and other criteria: General discussion. *Faraday Discuss.* **2018**, *211*, 325–381. [[CrossRef](#)] [[PubMed](#)]
8. Sun, G.; Liu, X.; Abramov, Y.A.; Nilsson Lill, S.O.; Chang, C.; Burger, V.; Broo, A. Current State-of-the-art In-house and Cloud-Based Applications of Virtual Polymorph Screening of Pharmaceutical Compounds: A Challenging Case of AZD1305. *Cryst. Growth Des.* **2021**, *21*, 1972–1983. [[CrossRef](#)]
9. Neumann, M.A.; van de Streek, J.; Fabbiani, F.P.A.; Hidber, P.; Grassmann, O. Combined crystal structure prediction and high-pressure crystallization in rational pharmaceutical polymorph screening. *Nat. Commun.* **2015**, *6*, 7793–7799. [[CrossRef](#)]
10. Baaklini, G.; Dupray, V.; Coquerel, G. Inhibition of the spontaneous polymorphic transition of pyrazinamide γ form at room temperature by co-spray drying with 1,3-dimethylurea. *Int. J. Pharm. (Amst. Neth.)* **2015**, *479*, 163–170. [[CrossRef](#)]
11. Smets, M.M.H.; Baaklini, G.; Tijink, A.; Sweers, L.; Vossen, C.H.F.; Brandel, C.; Meekes, H.; Cuppen, H.M.; Coquerel, G. Inhibition of the Vapor-Mediated Phase Transition of the High Temperature Form of Pyrazinamide. *Cryst. Growth Des.* **2018**, *18*, 1109–1116. [[CrossRef](#)]
12. Li, K.; Gbabode, G.; Barrio, M.; Tamarit, J.-L.; Vergé-Depré, M.; Robert, B.; Rietveld, I.B. The phase relationship between the pyrazinamide polymorphs α and γ . *Int. J. Pharm.* **2020**, *580*, 119230. [[CrossRef](#)]
13. Li, K.; Gbabode, G.; Vergé-Depré, M.; Robert, B.; Barrio, M.; Itié, J.-P.; Tamarit, J.-L.; Rietveld, I.B. The pressure-temperature phase diagram of tetramorphic pyrazinamide. *CrystEngComm* **2022**, *24*, 5041–5051. [[CrossRef](#)]

14. Patyk-Kazmierczak, E.; Kazmierczak, M. A new high-pressure benzocaine polymorph—Towards understanding the molecular aggregation in crystals of an important active pharmaceutical ingredient (API). *Acta Crystallogr. B* **2020**, *76*, 56–64. [[CrossRef](#)] [[PubMed](#)]
15. Lynch, D.E.; McClenaghan, I. Monoclinic form of ethyl 4-aminobenzoate (benzocaine). *Acta Crystallogr. E* **2002**, *58*, O708–O709. [[CrossRef](#)]
16. Chan, E.J.; Rae, A.D.; Welberry, T.R. On the polymorphism of benzocaine; a low-temperature structural phase transition for form (II). *Acta Crystallogr. B* **2009**, *65*, 509–515. [[CrossRef](#)] [[PubMed](#)]
17. Chan, E.J.; Welberry, T.R. Precursor effects of the orthorhombic to monoclinic phase transition in benzocaine form (II) revealed by X-ray diffuse scattering. *Acta Crystallogr. B* **2010**, *66*, 260–270. [[CrossRef](#)] [[PubMed](#)]
18. Patel, M.A.; AbouGhaly, M.H.H.; Chadwick, K. The discovery and investigation of a crystalline solid solution of an active pharmaceutical ingredient. *Int. J. Pharm.* **2017**, *532*, 166–176. [[CrossRef](#)] [[PubMed](#)]
19. Baptista, A. Radiocrystallographic study of organic substances. III. Benzocaine. *An. Acad. Bras. Cienc.* **1968**, *40*, 67–70.
20. Sinha, B.K.; Pattabhi, V. Crystal-Structure of Benzocaine—a Local-Anesthetic. *P Indian -Chem Sci.* **1987**, *98*, 229–234. [[CrossRef](#)]
21. Rietveld, I.B.; Ceolin, R. Rotigotine: Unexpected Polymorphism with Predictable Overall Monotropic Behavior. *J. Pharm. Sci.* **2015**, *104*, 4117–4122. [[CrossRef](#)]
22. Céolin, R.; Rietveld, I.B. The topological pressure-temperature phase diagram of ritonavir, an extraordinary case of crystalline dimorphism. *Ann. Pharm. Fr.* **2015**, *73*, 22–30. [[CrossRef](#)]
23. Bauer, M.; Lacoulonche, F.; Ceolin, R.; Barrio, M.; Khichane, I.; Robert, B.; Tamarit, J.L.; Rietveld, I.B. On the dimorphism of prednisolone: The topological pressure-temperature phase diagram involving forms I and II. *Int. J. Pharm.* **2022**, *624*, 122047. [[CrossRef](#)] [[PubMed](#)]
24. Tsukushi, I.; Yamamuro, O.; Sadanami, K.; Nishizawa, M.; Matsuo, T.; Takeda, K. Construction of a top-loading adiabatic calorimeter and enthalpy relaxation of glassy (1,3-propanediol)0.5(1,2-propanediamine)0.5. *Rev. Sci. Instrum.* **1998**, *69*, 179–184. [[CrossRef](#)]
25. Roisnel, T.; Rodriguez-Carvajal, J. WinPLOTR: A Windows tool for powder diffraction pattern analysis. *Mater. Sci. Forum* **2001**, *378–381*, 118–123. [[CrossRef](#)]
26. Coelho, A.A. Indexing of powder diffracton patterns by iterative use of singular value decomposition. *J. Appl. Crystallogr.* **2003**, *36*, 86–95. [[CrossRef](#)]
27. Coelho, A.A. *TOPAS Academic version 4.1 (Computer Software)*; Coelho Software: Brisbane, Australia, 2007.
28. Würflinger, A. Differential thermal-analysis under high-pressure IV. Low-temperature DTA of solid-solid and solid-liquid transitions of several hydrocarbons up to 3 kbar. *Ber. Bunsen-Ges. Phys. Chem.* **1975**, *79*, 1195–1201. [[CrossRef](#)]
29. Yu, L. Inferring Thermodynamic Stability Relationship of Polymorphs from Melting Data. *J. Pharm. Sci.* **1995**, *84*, 966–974. [[CrossRef](#)] [[PubMed](#)]
30. Riecke, E. Spezielle Fälle von Gleichgewichterscheinungen eines aus mehreren Phasen zusammengesetzten Systemes. *Z. Phys. Chem. (Munich)* **1890**, *6*, 411–429. [[CrossRef](#)]
31. ACDLabs. *Advanced Chemistry Development (ACD/Labs) Software, V11.02*; ACD/Labs: Toronto, ON, Canada, 2012.
32. Ceolin, R.; Allouchi, H.; Rietveld, I.B. On the dimorphism and the pressure-temperature state diagram of gestodene, a steroidal progestogen contraceptive. *Ann Pharm Fr* **2020**, *78*, 303–309. [[CrossRef](#)]
33. Toscani, S.; de Oliveira, P.; Céolin, R. Phenomenology of polymorphism IV. The trimorphism of ferrocene and the overall metastability of its triclinic phase. *J. Solid State Chem.* **2002**, *164*, 131–137. [[CrossRef](#)]
34. Toscani, S.; Céolin, R.; Ter Minassian, L.; Barrio, M.; Veglio, N.; Tamarit, J.-L.; Louër, D.; Rietveld, I.B. Stability hierarchy between piracetam forms I, II, and III from experimental pressure-temperature diagrams and topological inferences. *Int. J. Pharm.* **2016**, *497*, 96–105. [[CrossRef](#)]
35. Nicolai, B.; Barrio, M.; Lloveras, P.; Polian, A.; Itie, J.P.; Tamarit, J.L.; Rietveld, I.B. A thermodynamically consistent phase diagram of a trimorphic pharmaceutical, l-tyrosine ethyl ester, based on limited experimental data. *Phys Chem Chem Phys* **2018**, *20*, 24074–24087. [[CrossRef](#)] [[PubMed](#)]
36. Barrio, M.; de Oliveira, P.; Céolin, R.; Lopez, D.O.; Tamarit, J.L. Polymorphism of 2-methyl-2-chloropropane and 2,2-dimethylpropane (neopentane): Thermodynamic evidence for a high-pressure orientationally disordered rhombohedral phase through topological p-T diagrams. *Chem. Mater.* **2002**, *14*, 851–857. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.